Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
NCT06410300 is an observational study sponsored by Bo Lu. As of 21 Nov 2026, it is recruiting participants. It studies Immunotherapy in Lung Cancer. The registry lists an enrollment of 125 participants at 3 sites in 1 country. The registry lists a start date of 19 Apr 2024 and a primary completion date of 19 Apr 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06410300 |
| Status | Recruiting |
| Study type | Observational study |
| Lead sponsor | Bo Lu |
| Enrollment | 125 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Lung Cancer |
| Drugs | Immunotherapy |
| Start | 19 Apr 2024 |
| Primary completion | 19 Apr 2028 |
| Study completion | 19 Apr 2030 |
| Last update posted | 30 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Bo Lu, MD
Chair, Department of Radiation Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Missouri - Ellis Fischel Cancer Center
Columbia
Bo Lu, MDGregory Biedermann, MDRuobing Xue, MDRecruiting
- Rutgers Cancer Institute of New Jersey
New Brunswick
Salma Jabbour, MDRecruiting
- University of Rochester Medical Center
Rochester
Yuhchyau Chen, MD, PhDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06410300
Each answer restates registry values shown on this page.
What is NCT06410300?
NCT06410300 is an observational study sponsored by Bo Lu. It studies Immunotherapy in Lung Cancer.
Is NCT06410300 recruiting?
As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.
Who leads NCT06410300?
The registry names Bo Lu, MD (principal investigator, Chair, Department of Radiation Oncology) as the overall official.
Where does NCT06410300 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06410300 study?
The registered drug and biological interventions are Immunotherapy.
When is NCT06410300 expected to complete?
The registry lists a primary completion date of 19 Apr 2028 and a study completion date of 19 Apr 2030. The sponsor last updated the record on 30 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.